Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.48 |
| ▸ | CA12 | O43570 | 6/20 | 0.42 |
| ▸ | CA1 | P00915 | 6/20 | 0.42 |
| ▸ | CA2 | P00918 | 6/20 | 0.42 |
| ▸ | CA7 | P43166 | 6/20 | 0.42 |
| ▸ | CA9 | Q16790 | 6/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 6/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | NNMT | P40261 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | XDH | P47989 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL23530076 | 0.98 | MAPK1 (0.47) | MAPK1CA12CA1CA2CA7 | |
| SCHEMBL29442775 | 0.89 | MAPK1 (0.57) | MAPK1CA12CA1CA2CA7 | |
| SCHEMBL1456298 | 0.89 | MAPK1 (0.57) | MAPK1CA12CA1CA2CA7 | |
| SCHEMBL18979849 | 0.81 | KDM4E (0.56) | MAPK1CA12CA1CA2CA7 | |
| SCHEMBL14966683 | 0.81 | MAPK1 (0.50) | MAPK1CA12CA1CA2CA7 | |
| SCHEMBL31058092 | 0.81 | MAPK1 (0.50) | MAPK1CA12CA1CA2CA7 | |
| SCHEMBL11886132 | 0.79 | MAPK1 (0.48) | MAPK1CA12CA1CA2CA7 | |
| SCHEMBL1544504 | 0.79 | NNMT (0.66) | MAPK1CA1CA2KDM4EL3MBTL1 | |
| SCHEMBL31226268 | 0.79 | MAPK1 (0.48) | MAPK1CA12CA1CA2CA7 | |
| SCHEMBL5169193 | 0.79 | CYP1A2 (0.55) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043612-B2 | Methods of manufacturing a bifunctional compound, ultrapure forms of the bifunctional compound, and dosage forms comprising the same | ARVINAS OPERATIONS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-20230391795-A1 | MACROCYCLIC UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2023-12-07 | — | — | US | disclosed |
| EP-4236938-A1 | MACROCYCLIC UREA OREXIN RECEPTOR AGONISTS | Merck Sharp & Dohme LLC (US) | 2023-09-06 | — | — | EP | disclosed |
| CN-116600803-A | Macrocyclic urea orexin receptor agonists | 默沙东有限责任公司 | 2023-08-15 | — | — | CN | disclosed |
| US-20230012321-A1 | METHODS OF MANUFACTURING A BIFUNCTIONAL COMPOUND, ULTRAPURE FORMS OF THE BIFUNCTIONAL COMPOUND, AND DOSAGE FORMS COMPRISING THE SAME | ARVINAS OPERATIONS, INC. (US) | 2023-01-12 | — | — | US | disclosed |
| WO-2022094012-A1 | MACROCYCLIC UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2022-05-05 | — | — | WO | disclosed |
| WO-2022094012-A1 | MACROCYCLIC UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2022-05-05 | — | — | WO | disclosed |
| EP-3333157-B1 | VINYL COMPOUNDS AS FGFR AND VEGFR INHIBITORS | HARBIN ZHENBAO PHARMACEUTICAL CO LTD (CN) | 2020-12-23 | — | — | EP | disclosed |
| US-10519133-B2 | Vinyl compounds as FGFR and VEGFR inhibitors | MEDSHINE DISCOVERY INC. (CN) | 2019-12-31 | — | — | US | disclosed |
| US-20180222886-A1 | VINYL COMPOUNDS AS FGFR AND VEGFR INHIBITORS | Harbin Zhenbao Pharmaceutical Co., Ltd. (CN) | 2018-08-09 | — | — | US | disclosed |
| US-20080096895-A1 | Heterocyclic Derivatives and Their Use as Stearoyl-Coa Desaturase Inhibitors | XENON PHARMACEUTICALS INC. (CA) | 2008-04-24 | — | — | US | disclosed |
| US-7335658-B2 | Pyridazine derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2008-02-26 | — | — | US | disclosed |
| CN-101083994-A | Heterocyclic derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC (CA) | 2007-12-05 | — | — | CN | disclosed |
| EP-1807085-A2 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS STEAROYL-COA DESATURASE INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2007-07-18 | — | — | EP | disclosed |
| CN-1829698-A | Pyridazine derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC (CA) | 2006-09-06 | — | — | CN | disclosed |
| EP-1648874-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-04-26 | — | — | EP | disclosed |
| WO-2006034440-A2 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS STEAROYL-COA DESATURASE INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2006-03-30 | — | — | WO | disclosed |
| US-20060009459-A1 | Pyridazine derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2006-01-12 | — | — | US | disclosed |
| US-20050065143-A1 | Pyridazine derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2005-03-24 | — | — | US | disclosed |
| WO-2005011655-A2 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065143-A1 | Pyridazine derivatives and their use as therapeutic agents | PRDX5, SNRPD3, SNRPD2 | MAPK1 3803/4885CA12 4883/4885CA1 4882/4885 |
| US-12043612-B2 | Methods of manufacturing a bifunctional compound, ultrapure forms of the bifunctional compound, and dosage forms comprising the same | PAICS, UGT1A1, PBRM1 | MAPK1 3445/4885CA12 4207/4885CA1 4767/4885 |
| US-20080096895-A1 | Heterocyclic Derivatives and Their Use as Stearoyl-Coa Desaturase Inhibitors | SCD, SCD5, ECHS1 | MAPK1 4073/4885CA12 4874/4885CA1 4734/4885 |
| US-10519133-B2 | Vinyl compounds as FGFR and VEGFR inhibitors | FGFR1, FLT1, KDR | MAPK1 217/4885CA12 4050/4885CA1 4316/4885 |
| US-20230012321-A1 | METHODS OF MANUFACTURING A BIFUNCTIONAL COMPOUND, ULTRAPURE FORMS OF THE BIFUNCTIONAL COMPOUND, AND DOSAGE FORMS COMPRISING THE SAME | PAICS, UGT1A1, PBRM1 | MAPK1 3445/4885CA12 4207/4885CA1 4767/4885 |
| US-20180222886-A1 | VINYL COMPOUNDS AS FGFR AND VEGFR INHIBITORS | FGFR1, FLT1, KDR | MAPK1 217/4885CA12 4050/4885CA1 4316/4885 |
| US-20230391795-A1 | MACROCYCLIC UREA OREXIN RECEPTOR AGONISTS | HCRTR1, HCRTR2, CRHR1 | MAPK1 3762/4885CA12 3467/4885CA1 1248/4885 |
| US-20060009459-A1 | Pyridazine derivatives and their use as therapeutic agents | PRDX5, SNRPD3, C3AR1 | MAPK1 3816/4885CA12 4883/4885CA1 4881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.